Sep 20, 2023 04:43 AM
https://www.eurekalert.org/news-releases/1001651
INTRO: A new study published in a Nature Partner Journal, npj Microgravity, finds an engineered compound given to mice aboard the International Space Station (ISS) largely prevented the bone loss associated with time spent in space. The study, led by a transdisciplinary team of professors at the University of California at Los Angeles (UCLA) and the Forsyth Institute in Cambridge, Massachusetts, highlight a promising therapy to mitigate extreme bone loss from long-duration space travel as well as musculoskeletal degeneration on Earth.
Microgravity-induced bone loss has long been a critical concern for long-term space missions. Decreased mechanical loading due to microgravity induces bone loss at a rate 12-times greater than on Earth. Astronauts in low Earth orbit may experience bone loss up to 1% per month, endangering astronaut skeletal health and increasing risk for fractures during long-duration spaceflight and later in life.
The current mitigation strategy for bone loss relies on exercise-induced mechanical loading to promote bone formation but is far from perfect for crewmembers spending up to six months in microgravity. Exercise does not always prevent bone loss, takes up valuable crew time, and may be contraindicated for certain types of injuries.
The new study led by Chia Soo, MD, vice chair for research in the Division of Plastic and Reconstructive Surgery, professor in Departments of Surgery and Orthopaedic Surgery at UCLA David Geffen School of Medicine, investigated whether systemic delivery of NELL-like molecule-1 (NELL-1) can reduce microgravity induced bone loss. Discovered by Kang Ting, DMD, DMSc at the Forsyth Institute, NELL-1 is crucial for bone development and bone density maintenance. Professor Ting also led numerous studies to show that local delivery of NELL-1 can regenerate musculoskeletal tissues such as bone and cartilage... (MORE - details)
INTRO: A new study published in a Nature Partner Journal, npj Microgravity, finds an engineered compound given to mice aboard the International Space Station (ISS) largely prevented the bone loss associated with time spent in space. The study, led by a transdisciplinary team of professors at the University of California at Los Angeles (UCLA) and the Forsyth Institute in Cambridge, Massachusetts, highlight a promising therapy to mitigate extreme bone loss from long-duration space travel as well as musculoskeletal degeneration on Earth.
Microgravity-induced bone loss has long been a critical concern for long-term space missions. Decreased mechanical loading due to microgravity induces bone loss at a rate 12-times greater than on Earth. Astronauts in low Earth orbit may experience bone loss up to 1% per month, endangering astronaut skeletal health and increasing risk for fractures during long-duration spaceflight and later in life.
The current mitigation strategy for bone loss relies on exercise-induced mechanical loading to promote bone formation but is far from perfect for crewmembers spending up to six months in microgravity. Exercise does not always prevent bone loss, takes up valuable crew time, and may be contraindicated for certain types of injuries.
The new study led by Chia Soo, MD, vice chair for research in the Division of Plastic and Reconstructive Surgery, professor in Departments of Surgery and Orthopaedic Surgery at UCLA David Geffen School of Medicine, investigated whether systemic delivery of NELL-like molecule-1 (NELL-1) can reduce microgravity induced bone loss. Discovered by Kang Ting, DMD, DMSc at the Forsyth Institute, NELL-1 is crucial for bone development and bone density maintenance. Professor Ting also led numerous studies to show that local delivery of NELL-1 can regenerate musculoskeletal tissues such as bone and cartilage... (MORE - details)